摘要
Ela Tablet is a traditional ethnomedicinal formulation from Xinjiang, China, historically used to support organ function, promote renal health, and enhance male reproductive function. Clinical evidence indicated efficacy in reducing proteinuria in diabetic nephropathy (DN). However, the mechanisms unclear, and the absorbed and metabolized constituents following 4 days of oral administration have not been characterized. This study therefore aims to elucidate the mechanisms of Ela Tablet against renal fibrosis in DN rats by profiling the active constituents absorbed into the blood. Serum pharmacochemistry was initially characterized by UHPLC–HRMS, and network pharmacology analyses were performed to predict implicated signaling pathways. A DN rat model was then induced by streptozotocin with a high-fat, high-sugar diet. Inflammatory cytokines and ferrous iron (Fe 2+ ) in renal tissues were quantified, renal fibrosis was assessed by Masson staining, and protein expression was evaluated by Western blotting. Additionally, the gut microbiota was profiled by full-length 16S rRNA sequencing. The results demonstrated that serum pharmacochemistry analysis identified 29 components, and network pharmacology implicated the MAPK, TLR, and PI3K/AKT signaling pathways as well as oxidative stress–related pathways. Ela Tablet was found to reduce renal levels of TGF-β1, IL-6, IL-1β, TNF-α, and Fe 2+ , and to modulate the Nrf2/HO-1/GPX4, MAPK, TLR4/MyD88/NF-κB, and PI3K/AKT/GSK-3β pathways. Administration was also associated with modulation of the gut microbiota; these changes were linked to an increased relative abundance of beneficial bacteria. Collectively, these findings indicated that Ela Tablet exerts multi-mechanistic renoprotective effects against renal fibrosis in DN and provide a rationale for further clinical evaluation.
危险品化学品经营许可证(带存储)